Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain infection that affects some patients using the drug. The U.S. Food and Drug Administration today cleared the blood test which can help doctors determine whether […]
Samsung Biologics, the drug manufacturing business that a South Korean conglomerate formed earlier this year with the help of pharmaceutical services firm Quintiles, is partnering on a $300 million initiative with Biogen Idec (NASDAQ:BIIB). The joint venture, which will be based in South Korea, will develop, manufacture and market biosimilars, biological products that are similar […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biogen Idec (NASDAQ:BIIB) is on track to add a third multiple sclerosis therapy to its portfolio — one with blockbuster drug potential. The biotechnology company on Wednesday reported positive results from the second of two phase 3 trials on its MS drug candidate BG-12. In a two-year study, a twice daily dosage reduced the annualized […]
Biogen Idec (NASDAQ:BIIB) has received European approval on an injectable pen that delivers its top-selling multiple sclerosis drug Avonex. Avonex is used as a treatment for relapsing forms of MS. The drug slows the progression of physical disability and reduces relapses. Weston, Massachusetts-based Biogen Idec makes Avonex at a manufacturing facility in North Carolina’s Research […]